Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV-971 and donepezil in Alzheimer's disease
ChiCTR2100047830Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Apr 2021
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of sodium oligomannate and donepezil in Alzheimer's disease (AD) (4 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Clinical Dementia Rating Scale overall score. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
sodium oligomannatedonepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2100047830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047830.